Minaris Advanced Therapies Executive and Leadership Team

Orla Cloak, the Chief Executive Officer at Minaris Advanced Therapies, directs the overarching corporate strategy and long-term vision for the organization. Cloak manages the alignment of global manufacturing capabilities with the evolving needs of the cell and gene therapy market. By fostering partnerships with biotechnology firms, the Chief Executive Officer ensures the company maintains a competitive edge in GMP manufacturing and process development. This leadership role involves overseeing the integration of advanced testing services to support clients from early-stage development through commercial launch. Orla Cloak drives the expansion of international facilities to meet rising demand for viral vectors and vaccine production. Through rigorous oversight of quality standards and regulatory compliance, the Chief Executive Officer secures the company's position as a premier partner in the life sciences sector, ultimately accelerating the delivery of innovative therapies to patients worldwide.

William Burckardt, the Chief Financial Officer at Minaris Advanced Therapies, manages the financial health and capital allocation strategies of the organization. Burckardt oversees fiscal planning, budgeting, and investment initiatives that support the expansion of global manufacturing capacity. The Chief Financial Officer ensures that financial resources align with the company's mission to provide end-to-end services for cell and gene therapy clients. By monitoring market trends and operational costs, William Burckardt maintains the fiscal discipline necessary for sustainable growth in the competitive CDMO landscape. This leadership role involves coordinating with the executive team to evaluate potential acquisitions and infrastructure investments that enhance service offerings. Through precise financial reporting and risk management, the Chief Financial Officer supports the company's ability to deliver high-quality regulatory and manufacturing support, ensuring long-term stability while enabling the organization to invest in the advanced technologies required for modern medical breakthroughs.

Darwin Richardson, the Chief Operating Officer at Minaris Advanced Therapies, executes the daily operational strategy across the company's global manufacturing network. Richardson oversees the seamless integration of GMP manufacturing processes, ensuring that production schedules meet the rigorous demands of biotechnology clients. The Chief Operating Officer drives operational excellence by optimizing supply chain logistics and facility utilization for complex therapies such as CAR-T and viral vectors. By managing cross-functional teams, Darwin Richardson ensures that quality control and regulatory compliance remain central to every stage of the manufacturing lifecycle. This role involves streamlining internal workflows to improve efficiency and throughput, directly impacting the company's ability to support clients from early development to commercial launch. Through the implementation of standardized operational procedures, the Chief Operating Officer maintains high performance across all international sites, ensuring that the organization consistently delivers reliable, high-quality manufacturing services to the global healthcare market.

Ilya Koltover, the President, Minaris Advanced Testing at Minaris Advanced Therapies, directs the specialized division focused on biosafety and analytical testing. Koltover manages the development and execution of advanced testing protocols essential for the validation of cell and gene therapies. The President, Minaris Advanced Testing ensures that all analytical services meet international regulatory standards, providing critical support for vaccine and viral vector development. By overseeing laboratory operations and technical staff, Ilya Koltover guarantees the accuracy and reliability of data provided to clients throughout the manufacturing process. This leadership role involves integrating testing capabilities with broader manufacturing services to offer a comprehensive, end-to-end solution for biotechnology partners. Through the continuous improvement of testing methodologies, the President, Minaris Advanced Testing drives the company's commitment to quality and safety, ensuring that every therapy processed within the network adheres to the highest scientific benchmarks before reaching patients.

Hiroto Bando, the President (Japan) at Minaris Advanced Therapies, leads the strategic operations and market development within the Japanese region. Bando manages local facility performance and ensures that manufacturing services align with the specific regulatory and quality requirements of the Japanese healthcare market. The President (Japan) drives business growth by cultivating relationships with regional biotechnology firms and research institutions. By overseeing local teams, Hiroto Bando ensures that the company's global expertise in cell and gene therapy is effectively applied to meet the needs of local clients. This role involves coordinating with the global executive team to synchronize regional initiatives with the company's overarching mission of accelerating access to life-changing therapies. Through the management of regional operations and the promotion of high-quality manufacturing standards, the President (Japan) strengthens the company's presence in the Asian market, facilitating the successful development and commercialization of advanced medical treatments.

Shinobu Kuwae, the Chief Technology Officer at Minaris Advanced Therapies, architects the technical infrastructure required for complex cell and gene therapy manufacturing. Kuwae drives innovation in process development, ensuring that manufacturing platforms remain scalable and efficient for diverse therapeutic modalities like CAR-T. The Chief Technology Officer manages the implementation of cutting-edge automation and digital tools to enhance production precision across global facilities. By collaborating with research teams, Shinobu Kuwae optimizes manufacturing workflows to reduce time-to-market for critical vaccines and viral vectors. This role involves evaluating emerging technologies to maintain the company's status as a leader in advanced manufacturing solutions. Through the continuous refinement of technical protocols, the Chief Technology Officer ensures that all processes meet stringent biosafety and quality requirements, providing clients with reliable, high-performance manufacturing services that support the successful commercialization of life-changing medical treatments.